SeraCare Life Sciences Launches New Product to Evaluate NGS Assays

SeraCare Life Sciences’ precision medicine division has launched the Seraseq solid tumor mutation mix — I (AF20), a biosynthetic reference material engineered to evaluate next-generation sequencing tumor profiling assays.

The product features a mixture of mutations associated in oncogenes and tumor suppressor genes, serving as a quality rubric for the NGS tests by enabling evaluation of library preparation, sequencing and variant allele detection, the Milford, Mass., devicemaker said Wednesday.

The material is stable for two years under advised storage conditions and can undergo 10 freeze-thaw cycles without degradation, the company adds.

The product has been designated for research use only. — Jason Scott